Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0H8QL
|
|||
| Former ID |
DAP000722
|
|||
| Drug Name |
Mazindol
|
|||
| Synonyms |
mazindol; Mazanor; Sanorex; Teronac; Mazildene; 22232-71-9; Magrilon; Dimagrir; Mazindolum; Mazindole; Mazindolum [INN-Latin]; Terenac; AN 448; Mazindol [USAN:BAN:INN]; SAH 42548; CCRIS 3152; DEA No 1605; 5-(4-Chlorophenyl)-3,5-dihydro-2H-imidazo[2,1-a]isoindol-5-ol; 5-(4-Chlorophenyl)-2,5-dihydro-3H-imidazo[2,1-a]isoindol-5-ol; HSDB 3112; SA 42-548; 5-(4-Chlorophenyl)-2,3-dihydro-5-hydroxy-5H-imidazo[2,1-a]isoindole; EINECS 244-857-0; S 42548; CHEMBL781; 5-p-Chlorophenyl-2,3-dihydro-5H-imidazo(2,1-a)isoindol-5-ol; BRN 0546547; Diestet; Sanjorex; Solucaps; Teronak; Mazindol Medix Brand; Mazindol Novartis Brand; Mazindol Searle Brand; Mazindol Wyeth Brand; Medix Brand of Mazindol; Novartis Brand of Mazindol; Searle Brand of Mazindol; Wyeth Brand of Mazindol; AN 448;AN448; AN-448; Mazanor (TN); SANOREX (TN); Sanorex (TN); Mazindol (JAN/USP/INN); (+-)-5-(p-Chlorophenyl)-2,5-dihydro-3H-imidazo(2,1-a)isoindol-5-ol; 5-(4-Chlorophenyl)-2,3-dihydro-5-hydroxy-5H-imidazo(2,1-a)isoindole; 5-(4-chlorophenyl)-2,3-dihydroimidazo[1,2-b]isoindol-5-ol; 5-(p-Chlorophenyl)-2,5-dihydro-3H-imidazo(2,1-a)isoindol-5-ol; 5H-Imidazo(2,1-a)isoindol-5-ol, 5-(4-chlorophenyl)-2,3-dihydro; [3H]mazindol
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Obesity [ICD-11: 5B81; ICD-10: E66; ICD-9: 278] | Approved | [1], [2] | |
| Therapeutic Class |
Central Nervous System Stimulants
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H13ClN2O
|
|||
| Canonical SMILES |
C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC=C(C=C4)Cl)O
|
|||
| InChI |
1S/C16H13ClN2O/c17-12-7-5-11(6-8-12)16(20)14-4-2-1-3-13(14)15-18-9-10-19(15)16/h1-8,20H,9-10H2
|
|||
| InChIKey |
ZPXSCAKFGYXMGA-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 22232-71-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
5663207, 7847433, 7979864, 8152518, 10514045, 14897762, 24896596, 29223131, 46509094, 48416196, 49978900, 51064091, 53789697, 57322096, 85174591, 92711740, 99431540, 103206445, 103856500, 103919017, 104305195, 125345244, 126630564, 126665962, 129938107, 131305866, 134338010, 134993905, 136949640, 137154621, 143038295, 152034992, 152258665, 160647502, 160830559, 160963924, 163094692, 163393871, 164228469, 164814279, 178101312, 178101499, 179116764, 186022457, 198993257, 204388874, 223664711, 224771980, 226415324, 241041015
|
|||
| ChEBI ID |
CHEBI:6702
|
|||
| SuperDrug ATC ID |
A08AA05
|
|||
| SuperDrug CAS ID |
cas=022232719
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Norepinephrine transporter (NET) | Target Info | Modulator | [3], [4] |
| Panther Pathway | Adrenaline and noradrenaline biosynthesis | |||
| Reactome | Na+/Cl- dependent neurotransmitter transporters | |||
| WikiPathways | Monoamine Transport | |||
| NRF2 pathway | ||||
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4797). | |||
| REF 2 | Use of sibutramine and other noradrenergic and serotonergic drugs in the management of obesity. Endocrine. 2000 Oct;13(2):193-9. | |||
| REF 3 | Binding of [3H]mazindol to cardiac norepinephrine transporters: kinetic and equilibrium studies. Naunyn Schmiedebergs Arch Pharmacol. 2004 Jul;370(1):9-16. | |||
| REF 4 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.